EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function.
Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, Meydan C, Xia M, Shen H, Gutierrez J, Easwar Kumar V, Carrasco SE, Ouseph MM, Yamshon S, Martin P, Griess O, Shema E, Porazzi P, Ruella M, Brentjens RJ, Inghirami G, Zappasodi R, Chadburn A, Melnick AM, Béguelin W.
Isshiki Y, et al. Among authors: ouseph mm.
Cancer Cell. 2025 Jan 13;43(1):49-68.e9. doi: 10.1016/j.ccell.2024.11.006. Epub 2024 Dec 5.
Cancer Cell. 2025.
PMID: 39642889